$30 million private placement supports commercial team build-out to drive U.S. sales growth; Q3 U.S. sales increased slightly despite significant funding constraints prior to mid-August financingATLANTA, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announces its financ
ATLANTA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today the appointment of John Moorhead to its Board of Directors as a board designee in connection with the Company’s August 2026 private placement. Mr. Moorhead brings more than two decades of experience
First in a planned network of specialty pharmacy partnerships provides medication coordination and preferred pricing for OB/GYNs and their patientsATLANTA, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today an agreement with SandsRx Pharmacy, marking the firs
-- Twelve academic and private clinical sites across the U.S. broaden patient access to the pivotal trial as Femasys advances FemBloc toward potential FDA approval --ATLANTA, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that it has doubled the number of
Femasys is a commercial-stage medtech company targeting OB/GYNs with in-office fertility and permanent birth control solutions. See why FEMY stock is a Buy.
-- Leading multi-site OB/GYN health practice to implement FemVue® for fertility diagnostic evaluation and FemaSeed for first-line treatment across all four locations -- ATLANTA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that Minnesota Women’s Care w
-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue® fertility evaluation and FemaSeed as a first-line treatment option -- ATLANTA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today a partnership with UNC Health to
This is the newest page. Registered accounts read further back.